Provided by Tiger Fintech (Singapore) Pte. Ltd.

Johnson & Johnson

155.17
-1.6500-1.05%
Pre-market: 157.682.51+1.62%08:57 EDT
Volume:6.87M
Turnover:1.07B
Market Cap:373.35B
PE:17.27
High:157.19
Open:156.36
Low:154.80
Close:156.82
Loading ...

Johnson & Johnson Beats Earnings Estimates. Financial Chief Says It Can Do Any Deal It Wants

Dow Jones
·
2 hours ago

BUZZ-Legend Biotech up as Q2 sales for J&J-partnered blood cancer therapy rises

Reuters
·
23 mins ago

Pre-Bell|U.S. Futures Mixed; ASML Sinks 7% After Earnings; Crypto Stocks Shine With GAME up 48%, BTCS up 25%

Tiger Newspress
·
53 mins ago

Johnson & Johnson Keeps Quarterly Dividend at $1.30 a Share, Payable Sept. 9 to Shareholders of Record as of Aug. 26

MT Newswires Live
·
1 hour ago

BUZZ-U.S. STOCKS ON THE MOVE-Johnson & Johnson, Easterly Government Properties, Bank of America

Reuters
·
1 hour ago

BRIEF-J&J Anticipate Second Half Operational Sales Growth Higher Than First Half - Presentation

Reuters
·
1 hour ago

J&J: in Innovative Medicine, Negative Impact of Part D Re-Design, as a Percent to Sales, Will Be Consistently Applied Throughout Year

THOMSON REUTERS
·
1 hour ago

J&J: Products Negatively Impacted by Part D Re-Design Include Stelara, Invega Long Acting Injectables, Erleada, Opsumit, Uptravi, Tremfya & Imbruvica

THOMSON REUTERS
·
1 hour ago

J&J: Anticipate Second Half Operational Sales Growth Higher Than First Half - Presentation

THOMSON REUTERS
·
1 hour ago

Johnson & Johnson Shares Extend Gains, Last up 2.4% Premarket

THOMSON REUTERS
·
1 hour ago

3 Magnificent S&P 500 Dividend Stocks Down 16% to 20% to Buy and Hold Forever

Motley Fool
·
1 hour ago

The market's been wrong on the Fed for three straight years - this Deutsche Bank strategist says it's now looking like four.

Dow Jones
·
2 hours ago

Trump Threatens Pharma Tariffs This Month. Why the Stocks Are Looking Healthy. -- Barrons.com

Dow Jones
·
2 hours ago

Johnson & Johnson Beats Sales Forecasts as Trump Renews Tariff Threats

Deep News
·
2 hours ago

Johnson & Johnson lifts earnings guidance for the year

Dow Jones
·
2 hours ago

Genmab A/S Reports USD 3.54 Billion in Q2 2025 DARZALEX Net Sales

Reuters
·
2 hours ago

Johnson & Johnson Beats Profit Estimates On Strong Darzalex, Medtech Sales

Reuters
·
2 hours ago

GUIDANCE: (JNJ) Johnson & Johnson Expects 2025 Operational Sales Range $92.7B - $93.1B

MT Newswires Live
·
2 hours ago

Johnson & Johnson Announces Quarterly Dividend of $1.30 per Share for Third Quarter 2025

Reuters
·
2 hours ago

GUIDANCE: (JNJ) Johnson & Johnson Expects Full Year 2025 Adjusted EPS Range $10.80 - $10.90, vs. FactSet Est of $10.66

MT Newswires Live
·
2 hours ago